Evercore ISI resumed coverage of Argenx with an Outperform rating and $436 price target. While expectations have come down, the firm is “still cautious ahead of data” from the upcoming registrational CIDP readout in July, the analyst tells investors. However, while admitting to being cautious on the data release, the firm is “still constructive on the commercial opportunity” and “not bearish on the stock overall,” the analyst added.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ARGX:
- argenx announces launch of proposed global offering
- Argenx, Zai Lab Soar on Promising Data in CIDP
- Zai Lab, Argenx announce ADHERE study met primary endpoint
- argenx Reports Positive Topline Data from ADHERE Study of VYVGART Hytrulo in Patients with Chronic Inflammatory Demyelinating Polyneuropathy
- argenx and Zai Lab Announce Approval of VYVGART® (efgartigimod alfa injection) for Generalized Myasthenia Gravis in China